Inclusion Criteria

Inclusion Criteria

- 18 years of age

- Histologically confirmed grade 1 or 2 follicular B-cell lymphoma (WHO classification)

- Patients that have responded with at least stable disease to their most recent chemo-
or anti-CD20 antibody (Rituxan®, Zevalin, Bexxar) therapy for a minimum of 90 days
and who currently have relapsed or who continue to have stable disease.

- Tumor accessible for biopsy or previously existing biopsy material

- At least 1 additional bidimensional lesion measuring at least 2 cm in each dimension

- Performance status (ECOG) of 0, 1 or 2

- Absolute Granulocyte count ? 1,000/mm3

- Total Bilirubin < 2 mg/dL

- AST and ALT < 2x Upper Limit of Normal

- Creatinine < 1.5 mg/dL

Exclusion Criteria

- Patients who have had more than 3 prior chemotherapy or anti-CD20 regimens

- Prior fludarabine

- Prior tumor-specific idiotype immunotherapy

- Patients whose disease has progressed within the first 90 days of their last
chemotherapy or anti-CD20 treatment

- Concurrent immunosuppressive therapy (high-dose steroids; etc)

- Prior splenectomy

- Surgery, cancer radiotherapy, steroid therapy, immunotherapy or chemotherapy within
90 days prior to first scheduled vaccination

- Known history of CNS lymphoma or meningeal lymphomatosis

- HIV positive

- Serious non-malignant disease (e.g., psychiatric disorders, congestive heart failure,
or active uncontrolled bacterial, viral, or fungal infections), or other conditions
which, in the opinion of the investigator would compromise protocol objectives

- Prior malignancy (excluding nonmelanoma carcinomas of the skin and in situ cervical
carcinomas) unless in remission for > 2 years

- Treatment with an investigational drug within 30 days prior to study entry

- Pregnant or nursing women NOTE: Women of childbearing potential should be advised to
avoid becoming pregnant while receiving treatment with FavId.